扶正合剂联合化疗治疗老年晚期非小细胞肺癌疗效观察

Effect of Fuzheng mistura combined with chemotherapy on patients with non-small cell lung cancer in senile advanced stage

[目的]观察扶正合剂联合GP方案化疗治疗老年晚期非小细胞肺癌患者的临床疗效和毒副反应。[方法]选择50例经明确诊断的老年晚期非小细胞肺癌患者,随机分为两组,A组给予吉西他滨加卡铂方案(GP方案)静脉化疗,B组加用扶正合剂口服,28 d为1个周期,连续观察2个化疗周期。[结果]在缩小瘤体方面,B组临床受益率优于A组,差异有统计学意义(P<0.05);在降低血清肿瘤标志物方面,两组治疗前后癌胚抗原(CEA)水平变化差异有统计学意义(P<0.05),细胞角质素19片段(CYFRA-21)水平变化差异无统计学意义(P>0.05);两组患者在免疫功能、卡氏评分、临床症状改善方面,差异有统计性意义(P<0.05);在毒副反应方面,恶心呕吐、白细胞减少的B组发生率较A组低,两组差异均有统计学意义(P<0.05)。[结论]扶正合剂对老年晚期非小细胞肺癌化疗具有增效减毒的治疗作用。

[Objective] To observe the effect and side reaction of Fuzheng mistura combined with GP scheme chemotherapy on patients with non-small cell lung cancer in senile advanced stage. [Methods] Fifty patients with confirmed diagnosis of advanced non-small cell lung cancer were enrolled. They were randomly divided into two groups. Group A was given with gemcitabine plus carboplatin solution chemotherapy intravenously, and group B with Fuzheng mistura orally. Twenty-eight days was a course and the treatment was continuous- ly used for two chemotherapy courses. [Results] Fuzheng mistura in chemotherapy of older patients with advanced non small cell lung cancer had a therapeutic effect. In decreasing the cancer size the clinical benefit rate of group B was better than that of group A with sig- nificant difference （P〈0.05）. In reducing the serum tumor markers, the change of CEA level had significant difference （P〈0.05） of both groups before and after treatment. There was no statistical difference in CYFRA-21 level （P〉O.05）. There was significant difference （P〈 0.05） between two groups of patients in the improvement of immune function, casparian score, clinical symptoms. A significant differ- ences were also found in side reactions, nausea vomiting, decreasing of leucocyte count. Their incidence in group B was lower than that in group A. [Conclusion] Fuzheng mistura has effect-increasing and detoxification effect in chemotherapy in older patients with advanced non small cell lung cancer.